CDI

Snowplow Launches AI Agent Event Collection and Analytics on the Snowflake AI Data Cloud

Retrieved on: 
Martedì, Giugno 4, 2024
Software, Data Analytics, Internet, Artificial Intelligence, Data Management, Professional Services, Technology, Mobile, Wireless, Cloud, Cortex, Auto Trader, Data science, Investment, Collection, Strava, LLM, Synthetic media, CDI, AI, Organization, Burberry, ROI, Generative

Snowplow today announced at Snowflake’s annual user conference, Snowflake Data Cloud Summit 2024 , the launch of AI Agent Event Collection and Analytics, which is Powered by Snowflake .

Key Points: 
  • Snowplow today announced at Snowflake’s annual user conference, Snowflake Data Cloud Summit 2024 , the launch of AI Agent Event Collection and Analytics, which is Powered by Snowflake .
  • Building AI Agent Event Collection and Analytics on Snowflake’s AI Data Cloud has allowed Snowplow to use Snowflake Cortex AI to implement uplift modeling with LLM events and measure the incremental benefit of your LLM agents on customer conversion.
  • “It’s great to see partners such as Snowplow continue to invest in the AI Data Cloud to address these challenges faced by brands.
  • We’re excited to see how their AI Agent Event Analytics helps customers see the potential of Cortex AI in making better-informed business decisions.”
    With AI Agent Event Collection and Analytics, Powered by Snowflake, joint customers will be able to collect usage analytics for the AI agent and calculate sentiment analysis for the conversation.

Churchill Downs Incorporated Names Sam Ullrich Vice President of Investor Relations

Retrieved on: 
Mercoledì, Maggio 29, 2024
PwC, CHDN, Restaurant, KFC, University, Assurance, CDI, Commercial, Financial plan, LLP, Certified Public Accountant, YUM, Management

LOUISVILLE, Ky., May 29, 2024 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company," "CDI") announced today that Sam Ullrich has been named Vice President of Investor Relations for the Company.

Key Points: 
  • LOUISVILLE, Ky., May 29, 2024 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company," "CDI") announced today that Sam Ullrich has been named Vice President of Investor Relations for the Company.
  • In this role, Ullrich will be responsible for all aspects of investor relations and work closely with current and prospective shareholders and analysts.
  • He will report to Marcia Dall, Executive Vice President and Chief Financial Officer for CDI.
  • Prior to joining CDI, Ullrich was the Director, Commercial and Financial Planning, for Kentucky Fried Chicken Corporation (“KFC”), a YUM!

Churchill Downs Incorporated Opens Terre Haute Casino Resort Hotel in Terre Haute, Indiana

Retrieved on: 
Mercoledì, Maggio 15, 2024
Terre Haute, Indiana, Table, CHDN, CDI, Food, Casino

LOUISVILLE, Ky., May 15, 2024 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (“CDI” or “the Company”) (Nasdaq: CHDN) today announced the opening of its new 122-room hotel and event center at Terre Haute Casino Resort.

Key Points: 
  • LOUISVILLE, Ky., May 15, 2024 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (“CDI” or “the Company”) (Nasdaq: CHDN) today announced the opening of its new 122-room hotel and event center at Terre Haute Casino Resort.
  • Terre Haute Casino Resort offers regionally inspired food and beverage amenities including the Four Cornered Steakhouse, Rockwood Bar & Grill, The Soda Shoppe, Crossroads Center Bar and High Limit Bar.
  • “Terre Haute Casino Resort has already attracted thousands of visitors from the region to enjoy an unparalleled gaming experience,” said Bill Carstanjen, CEO of CDI.
  • “The opening of the new luxury hotel component furthers our commitment to bringing new vibrancy to Terre Haute with this premier entertainment destination and marks a significant milestone for Churchill Downs Incorporated.”
    The development of Terre Haute Casino Resort generated nearly 1,000 construction jobs and will continue to provide approximately 550 full-time and part-time jobs to the region.

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

Retrieved on: 
Martedì, Maggio 21, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, Recurrence, Clostridioides difficile infection, Risk, Food, AGAF, Variometer, PRTC, CDI, FACG, Safety, Hospital, Death, Yale School of Medicine, Biologics license application, Clostridioides, BLA, Therapy, Pivotal, Quality of life, Infection, Pharmaceutical industry

The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration.

Key Points: 
  • The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration.
  • VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI).
  • “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program.
  • “CDI may recur in 25% or more of those affected, sometimes repeatedly, despite initially successful antibiotic treatment.

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

Retrieved on: 
Martedì, Maggio 21, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Vedanta, Risk, Food, AGAF, Variometer, Recurrence, CDI, FACG, Clostridioides difficile infection, Safety, Hospital, Death, Yale School of Medicine, Biologics license application, BLA, Therapy, Quality of life, Infection, Pharmaceutical industry

Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study.
  • VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI).
  • “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program.
  • “CDI may recur in 25% or more of those affected, sometimes repeatedly, despite initially successful antibiotic treatment.

Almonty Receives Further and Final Commitments Under Previously Announced Placement; Manages Dundee Resources Limited’s Divestment of Almonty Holding

Retrieved on: 
Martedì, Maggio 21, 2024
Mining, Minerals, Natural Resources, ASX, CDN, AII, Investment, Lead, CDI, Sale, Placement, ALI, TSX, Security (finance)

In addition, the Company has received firm commitments to raise further gross proceeds of A$1,194,500.06 pursuant to the issuance of 1,926,613 CDIs at A$0.62 per CDI Unit.

Key Points: 
  • In addition, the Company has received firm commitments to raise further gross proceeds of A$1,194,500.06 pursuant to the issuance of 1,926,613 CDIs at A$0.62 per CDI Unit.
  • This represents the final tranche of the March 2024 placement which is now closed.
  • Settlement of this final tranche is expected to occur on or around Monday 27 May 2024 with allotment on or around Tuesday 28 May 2024.
  • We have also been working hard alongside Dundee in finalising the divestment of their holding in Almonty, which has been successfully placed to supportive existing institutions and high net worth investors.”

First Real-World Outcomes Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at DDW 2024

Retrieved on: 
Lunedì, Maggio 20, 2024
Biotechnology, General Health, Pharmaceutical, Health, OLS, DDW, Patient, Phase 3, PPI, Ferring Pharmaceuticals, Risk, Food, AGAF, Clostridioides difficile infection, Recurrence, FDA, PUNCH, CDI, FACG, Clostridioides difficile, Mitt, Safety, Enzyme inhibitor, Bacteria, Dysbiosis, MD, Yale School of Medicine, Poster, Gastrointestinal disease, Multimedia, Roger Hawkins (drummer), Infection, Pharmaceutical industry

Those with 8-week follow-up were further evaluated and the efficacy of REBYOTA was assessed as the absence of recurrence at 8 weeks after administration.

Key Points: 
  • Those with 8-week follow-up were further evaluated and the efficacy of REBYOTA was assessed as the absence of recurrence at 8 weeks after administration.
  • Nearly 74% of these patients (25/34) maintained the effectiveness of REBYOTA at eight weeks, despite having a higher risk of further recurrence.
  • In the analysis, most TEAEs were mild or moderate gastrointestinal disorders and related to preexisting conditions or C. diff infection.
  • For at least six months, the number of REBYOTA responders with engraftment continued to rise and persist.

Alcoa Announces Update on Acquisition of Alumina Limited

Retrieved on: 
Lunedì, Maggio 20, 2024
Natural Resources, Manufacturing, Mining, Minerals, Steel, Australian Securities Exchange, CITIC, CDI, Agreement, CITIC Group, Proprietary company, Scheme, Acquisition, UBS, AA, Competition, Bank Holding Company Act, Aluminium

Alcoa Corp. (NYSE: AA or “Alcoa”) today announced it has entered into a Deed of Amendment and Restatement (the “Amendment”) of the Scheme Implementation Deed previously announced March 11, 2024 (the “Agreement”) with Alumina Limited in relation to the acquisition of Alumina Limited (the "Scheme").

Key Points: 
  • Alcoa Corp. (NYSE: AA or “Alcoa”) today announced it has entered into a Deed of Amendment and Restatement (the “Amendment”) of the Scheme Implementation Deed previously announced March 11, 2024 (the “Agreement”) with Alumina Limited in relation to the acquisition of Alumina Limited (the "Scheme").
  • Alumina Limited shareholders will continue to receive the previously announced Scheme Consideration of 0.02854 New CHESS Depositary Interests (“New Alcoa CDIs") or equivalent for each Alumina Limited share (the “Agreed Ratio”).
  • Each New Alcoa CDI represents a unit of beneficial ownership in a share of Alcoa common stock.
  • Alumina Limited shareholders will be able to trade Alcoa common stock via the New Alcoa CDIs, which will be listed on the Australian Securities Exchange (“ASX”).

Almonty Receives Further Commitments For A$1.9M Under Previously Announced Placement

Retrieved on: 
Sabato, Maggio 11, 2024
Mining, Minerals, Natural Resources, ASX, Lead, CDI, AII, ALI, TSX, Placement, Security (finance)

Almonty Industries Inc. (“Almonty” or the “Company”) (TSX: AII / ASX: AII / OTCQX: ALMTF / Frankfurt: ALI) is pleased to announce that following its March 2024 Placement, the Company has received firm commitments to raise further gross proceeds of A$1,860,000 via the issuance of 3,000,000 Placement Chess Depository Interests Units (“CDIs”) at A$0.62 per CDI Unit (“Placement”).

Key Points: 
  • Almonty Industries Inc. (“Almonty” or the “Company”) (TSX: AII / ASX: AII / OTCQX: ALMTF / Frankfurt: ALI) is pleased to announce that following its March 2024 Placement, the Company has received firm commitments to raise further gross proceeds of A$1,860,000 via the issuance of 3,000,000 Placement Chess Depository Interests Units (“CDIs”) at A$0.62 per CDI Unit (“Placement”).
  • Proceeds from the Placement will be applied towards general working capital and offer costs.
  • The closing of the Placement is subject to receipt of all necessary regulatory approvals, including the acceptance by the TSX and ASX.
  • RM Corporate Finance Pty Ltd acted as Lead Manager to the Placement and will be paid a total fee of 6% of the gross proceeds.

Life360 announces S-3 Filing

Retrieved on: 
Giovedì, Maggio 9, 2024
Sale, Prospectus, CHESS, Growth, Form, IPO, CDI, Australian Securities Exchange, The Company, Security (finance)

SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- San Francisco area-based Life360, Inc. ("Life360" or the "Company") today announced that it has publicly filed an automatically effective registration statement on Form S-3 (Registration No. 333-279271) (including a base prospectus) with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common stock in the U.S. (the "U.S. IPO"). The number of shares to be offered and the price range for the proposed offering have not yet been determined. Life360 intends to list its common stock on the Nasdaq Global Select Market under the symbol "LIF."

Key Points: 
  • Life360 Files Registration Statement for Proposed U.S.
  • Initial Public Offering
    SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- San Francisco area-based Life360, Inc. ("Life360" or the "Company") today announced that it has publicly filed an automatically effective registration statement on Form S-3 (Registration No.
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Life360 intends to list its common stock on the Nasdaq Global Select Market under the symbol "LIF."